资金逆势流入，生物医药ETF（159859）昨日“吸金”3536万元，为同标的产品第一

Group 1 - The Shanghai Composite Index turned positive on May 27, with the Biopharmaceutical ETF (159859) rising by 0.28% at the time of reporting [1] - Notable gainers within the Biopharmaceutical ETF included Dizhe Pharmaceutical-U, which increased by over 3%, along with Teva Biopharmaceuticals, Kailaiying, and Wantai Biological Pharmacy [1] - The Innovative Drug ETF Tianhong (517380) saw a decline of 0.33%, with Zhejiang Pharmaceutical rising by over 3%, while Ruizhi Pharmaceutical dropped by 3% [1] Group 2 - On May 26, the Biopharmaceutical ETF (159859) experienced a net inflow of 35.36 million yuan despite a drop of 0.57%, while the Innovative Drug ETF Tianhong (517380) had a net inflow of 3.6 million yuan despite a decline of 1.64% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ), which includes the top 30 securities in the biopharmaceutical sector based on market capitalization and liquidity [1] - The Innovative Drug ETF Tianhong, launched in 2021, has a scale of 389 million yuan as of May 26, and is the only product covering the entire market for the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [2] Group 3 - Minsheng Securities remains optimistic about the pharmaceutical sector, particularly in the innovative drug and new consumption areas, highlighting ongoing catalysts in the innovative drug sector [2] - Key focus areas for the innovative drug sector include anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy directions, along with an emphasis on domestic production and medical consumption, especially in the beauty sector [2]